Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.
Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG, Vuong L, Ostrovnaya I, Chen YB, Reuter V, Riaz N, Cheng Y, Patel P, Marker M, Reising A, Li MO, Chan TA, Motzer RJ. Hakimi AA, et al. Among authors: chen yb. Cancer Discov. 2019 Apr;9(4):510-525. doi: 10.1158/2159-8290.CD-18-0957. Epub 2019 Jan 8. Cancer Discov. 2019. PMID: 30622105 Free PMC article. Clinical Trial.
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.
Al-Ahmadie HA, Iyer G, Janakiraman M, Lin O, Heguy A, Tickoo SK, Fine SW, Gopalan A, Chen YB, Balar A, Riches J, Bochner B, Dalbagni G, Bajorin DF, Reuter VE, Milowsky MI, Solit DB. Al-Ahmadie HA, et al. Among authors: chen yb. J Pathol. 2011 Jun;224(2):270-9. doi: 10.1002/path.2892. Epub 2011 May 5. J Pathol. 2011. PMID: 21547910 Free PMC article.
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, Hsieh JJ; ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators. Hakimi AA, et al. Among authors: chen yb. Clin Cancer Res. 2013 Jun 15;19(12):3259-67. doi: 10.1158/1078-0432.CCR-12-3886. Epub 2013 Apr 25. Clin Cancer Res. 2013. PMID: 23620406 Free PMC article.
Renal tumors: diagnostic and prognostic biomarkers.
Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel. Tan PH, et al. Am J Surg Pathol. 2013 Oct;37(10):1518-31. doi: 10.1097/PAS.0b013e318299f12e. Am J Surg Pathol. 2013. PMID: 24025522 Free PMC article.
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.
Chen YB, Brannon AR, Toubaji A, Dudas ME, Won HH, Al-Ahmadie HA, Fine SW, Gopalan A, Frizzell N, Voss MH, Russo P, Berger MF, Tickoo SK, Reuter VE. Chen YB, et al. Am J Surg Pathol. 2014 May;38(5):627-37. doi: 10.1097/PAS.0000000000000163. Am J Surg Pathol. 2014. PMID: 24441663 Free PMC article.
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.
Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, Russo P, Cheng EH, Motzer RJ, Berger MF, Hsieh JJ. Voss MH, et al. Among authors: chen yb. Clin Cancer Res. 2014 Apr 1;20(7):1955-64. doi: 10.1158/1078-0432.CCR-13-2345. Epub 2014 Mar 12. Clin Cancer Res. 2014. PMID: 24622468 Free PMC article.
1,208 results